Page last updated: 2024-12-11
incarvillateine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
incarvillateine: isolated from the plant Incarvillea sinensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Incarvillea | genus | [no description available] | Bignoniaceae | A plant family of the order Lamiales. The family is characterized by oppositely paired, usually compound leaves and bell- or funnel-shaped, bisexual flowers having a five-lobed calyx and corolla.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9875096 |
| CHEMBL ID | 505819 |
| MeSH ID | M0350221 |
Synonyms (5)
| Synonym |
|---|
| incarvillateine |
| CHEMBL505819 |
| bis[(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridin-6-yl] 2,4-bis(4-hydroxy-3-methoxyphenyl)cyclobutane-1,3-dicarboxylate |
| 129748-10-3 |
| DTXSID901046113 |
Research Excerpts
Overview
Incarvillateine (INCA) is a natural product that has garnered attention due to its purported analgesic effects and historical use as a pain reliever in China.
| Excerpt | Reference | Relevance |
|---|---|---|
| "(-)-Incarvillateine (INCA) is a natural product that has garnered attention due to its purported analgesic effects and historical use as a pain reliever in China. " | ( Incarvillateine produces antinociceptive and motor suppressive effects via adenosine receptor activation. Awwa, M; Bogdan, DM; Che, J; Deutsch, DG; Elmes, MW; Kaczocha, M; Kim, J; Lee, G; Ojima, I; Rizzo, RC; Yan, S, 2019) | 2.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1301962 | Antinociceptive effect in Kunming mouse assessed as inhibition of acetic acid-induced writhing response at 20 mg/kg, sc administered 30 mins prior to acetic acid challenge measured 5 mins post injection for 15 mins | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID381216 | Antinociceptive activity against formalin-induced pain in ip dosed ddY mouse assessed as reduction of paw licking response during inflammatory phase pretreated for 10 mins before formalin challenge | 1999 | Journal of natural products, Sep, Volume: 62, Issue:9 | Strong antinociceptive effect of incarvillateine, a novel monoterpene alkaloid from Incarvillea sinensis. |
| AID1301972 | Antinociceptive effect in C57BL/6 mouse assessed as inhibition of spared nerve injury-induced neuropathic pain response at 10 to 20 mg/kg, ip measured after 5 to 7 days of recovery by Von Frey filament assay | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID381218 | Antinociceptive activity against formalin-induced pain in ip dosed ddY mouse assessed as reduction of paw licking response during inflammatory phase pretreated for 10 mins before formalin challenge relative to morphine | 1999 | Journal of natural products, Sep, Volume: 62, Issue:9 | Strong antinociceptive effect of incarvillateine, a novel monoterpene alkaloid from Incarvillea sinensis. |
| AID1301971 | Antinociceptive activity in ip dosed ICR mouse assessed as reduction in licking and biting time during second phase administered 10 mins prior to formalin challenge measured for 10 to 30 mins relative to vehicle control | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID381215 | Antinociceptive activity against formalin-induced pain in ip dosed ddY mouse assessed as reduction of paw licking response during neurogenic phase pretreated for 10 mins before formalin challenge | 1999 | Journal of natural products, Sep, Volume: 62, Issue:9 | Strong antinociceptive effect of incarvillateine, a novel monoterpene alkaloid from Incarvillea sinensis. |
| AID1301966 | Antinociceptive activity in ICR mouse assessed as reduction in licking and biting time during second phase at 10 mg/kg, ip administered 10 mins prior to formalin challenge measured for 10 to 30 mins (Rvb = 159 +/- 25 s) | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID1301970 | Antinociceptive activity in ip dosed ICR mouse assessed as reduction in licking and biting time during first phase administered 10 mins prior to formalin challenge measured for 10 mins relative to vehicle control | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID1301965 | Antinociceptive activity in ICR mouse assessed as reduction in licking and biting time during first phase at 20 mg/kg, ip administered 10 mins prior to formalin challenge measured for 10 mins (Rvb = 156 +/- 8 s) | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID1301967 | Antinociceptive activity in ICR mouse assessed as reduction in licking and biting time during second phase at 20 mg/kg, ip administered 10 mins prior to formalin challenge measured for 10 to 30 mins (Rvb = 159 +/- 25 s) | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID1301963 | Antinociceptive effect in Kunming mouse assessed as inhibition of acetic acid-induced writhing response at 20 mg/kg, ip administered 30 mins prior to acetic acid challenge measured 5 mins post injection for 15 mins | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID1301964 | Antinociceptive activity in ICR mouse assessed as reduction in licking and biting time during first phase at 10 mg/kg, ip administered 10 mins prior to formalin challenge measured for 10 mins (Rvb = 156 +/- 8 s) | 2016 | Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8 | Gram Scale Syntheses of (-)-Incarvillateine and Its Analogs. Discovery of Potent Analgesics for Neuropathic Pain. |
| AID381217 | Antinociceptive activity against formalin-induced pain in ip dosed ddY mouse assessed as reduction of paw licking response during neurogenic phase pretreated for 10 mins before formalin challenge relative to morphine | 1999 | Journal of natural products, Sep, Volume: 62, Issue:9 | Strong antinociceptive effect of incarvillateine, a novel monoterpene alkaloid from Incarvillea sinensis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||